We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Neose Technologies, Inc. today identified Factors VIIa, VIII and IX as the three proteins that are the subject of license agreements it entered into with Novo Nordisk A/S in November 2003.
Israel-based Intec Pharma has entered into a collaboration agreement with Impax Laboratories to develop a drug using Intec's Accordion Pill technology.
Japan-based Takeda Pharmaceutical and U.S.-based Affymax have entered into a global agreement to develop and commercialize Affymax's lead product candidate, Hematide, for the treatment of anemia.
Pharmaceutical wholesalers in Europe need to evolve to meet the changing pharma market and a world of opportunity awaits for those willing to think beyond their traditional business model and move to compete in the outsourcing arena.
AEterna Zentaris Inc. today announced that it presented Abstract No. P3-257 during a poster presentation entitled "ZEN-019, A Peptidomimetic from a New Class of Orally Active GnRH (LHRH) Antagonists," on Monday, June 26, 2006 in the Exhibit Hall of the Boston Convention & Exhibition Center in Boston, Massachusetts, during the 2006 Annual Meeting of the Endocrine Society.
Intec Pharma, developer of the Accordion Pill gastric retention technology, announced today that it has entered into a collaboration agreement with Impax Laboratories Inc. a leading US specialty pharmaceutical company in order to develop a CNS drug.
Affymax, Inc. and Takeda Pharmaceutical Company Limited today announced that the companies have entered into an exclusive global agreement to develop and commercialize Affymax's lead product candidate, Hematide, for the treatment of anemia.